Biocon Limited (IN:BIOCON)
:BIOCON
BIOCON Stock Chart & Stats
₹364.20
₹0.80(0.22%)
At close: 4:00 PM EST
₹364.20
₹0.80(0.22%)
Day’s Range― - ―
52-Week Range₹295.30 - ₹424.95
Previous CloseN/A
Volume1.20M
Average Volume (3M)208.50K
Market Cap
₹599.31B
Enterprise Value₹624.04B
Total Cash (Recent Filing)₹64.69B
Total Debt (Recent Filing)₹165.35B
Price to Earnings (P/E)91.6
Beta1.13
Next Earnings
May 14, 2026EPS Estimate
1.52Next Dividend Ex-DateN/A
Dividend Yield0.12%
Share Statistics
EPS (TTM)0.95
Shares Outstanding1,620,907,700
10 Day Avg. Volume177,351
30 Day Avg. Volume208,504
Financial Highlights & Ratios
PEG Ratio-38.08
Price to Book (P/B)1.88
Price to Sales (P/S)2.66
P/FCF Ratio23.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹437.00Price Target Upside19.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)4.32
Revenue Forecast (FY)₹171.05B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue Growth & ProfitabilitySustained revenue growth and overall profitability indicate durable demand for Biocon's products and services. Strong top-line expansion combined with solid net margins supports ongoing R&D, capacity build-out and partner economics, underpinning cash generation over the medium term.
Healthy Capital Structure And Cash GenerationA robust equity base and manageable leverage reduce refinancing risk while increased operating cash flow and positive free cash flow demonstrate the business can fund operations and investments internally, supporting strategic initiatives and capital allocation over the coming months.
Diversified Biopharma Business ModelMultiple durable revenue streams—biosimilars, generics, CDMO services and licensing—lower concentration risk and smooth revenue cycles. This diversification supports scale advantages in manufacturing and partnerships, sustaining revenue resilience and long-term commercial optionality.
Bears Say
Rising Total Debt RiskAn upward trend in total debt, even from reasonable leverage levels, can raise interest and rollover risk. If revenue or margins soften, higher debt amplifies cash flow pressure and limits strategic flexibility for R&D, capacity spending or acquisitions over the medium term.
Declining EBIT MarginA falling EBIT margin signals creeping cost pressures or pricing erosion that can persist across quarters. Reduced operational profitability constrains reinvestment, compresses free cash flow conversion and weakens earnings resilience unless structural cost or pricing improvements are executed.
Negative EPS GrowthMaterial negative EPS growth despite revenue gains indicates margin or non-operating headwinds (higher costs, interest, or one-offs). Persistent EPS decline undermines per-share earnings power, limiting retained earnings and reducing capacity to finance growth internally.
Biocon Limited News
BIOCON FAQ
What was Biocon Limited’s price range in the past 12 months?
Biocon Limited lowest stock price was ₹295.30 and its highest was ₹424.95 in the past 12 months.
What is Biocon Limited’s market cap?
Biocon Limited’s market cap is ₹599.31B.
When is Biocon Limited’s upcoming earnings report date?
Biocon Limited’s upcoming earnings report date is May 14, 2026 which is in 45 days.
How were Biocon Limited’s earnings last quarter?
Biocon Limited released its earnings results on Feb 12, 2026. The company reported ₹0.947 earnings per share for the quarter, missing the consensus estimate of ₹1.166 by -₹0.219.
Is Biocon Limited overvalued?
According to Wall Street analysts Biocon Limited’s price is currently Undervalued.
Does Biocon Limited pay dividends?
Biocon Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.12%. See more information on Biocon Limited dividends here
What is Biocon Limited’s EPS estimate?
Biocon Limited’s EPS estimate is 1.52.
How many shares outstanding does Biocon Limited have?
Biocon Limited has 1,620,907,700 shares outstanding.
What happened to Biocon Limited’s price movement after its last earnings report?
Biocon Limited reported an EPS of ₹0.947 in its last earnings report, missing expectations of ₹1.166. Following the earnings report the stock price went down -0.146%.
Which hedge fund is a major shareholder of Biocon Limited?
Currently, no hedge funds are holding shares in IN:BIOCON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biocon Limited
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and large molecules. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.
BIOCON Stock 12 Month Forecast
Average Price Target
₹437.00
▲(19.99% Upside)
Technical Analysis
Blue Jet Healthcare Limited
―
Concord Biotech Ltd.
―
Jubilant Ingrevia Ltd.
―
Piramal Pharma Limited
―
Syngene International Ltd.
―